Gracell Biotechnologies : Corporate Presentation - June 2021

Gracell Biotechnologies

Pioneering the Next Generation of CAR-T Cell Therapies

Corporate Presentation | JUNE 2021

GRCL (NASDAQ) I gracellbio.com

Disclaimer

This presentation has been prepared by Gracell Biotechnologies Inc. (the "Company") solely for information purpose and has not been independently verified. By viewing or accessing the information contained in this presentation, the recipient hereby acknowledges and agrees that no representations, warranties or undertakings, express or implied, are made by the Company or any of its directors, shareholders, employees, agents, affiliates, advisors or representatives as to, and no reliance should be placed upon, the accuracy, fairness, completeness or correctness of the information or opinions presented or contained in this presentation. None of the Company or any of its directors, shareholders, employees, agents, affiliates, advisors or representatives accept any responsibility whatsoever (in negligence or otherwise) for any loss howsoever arising from any information presented or contained in this presentation or otherwise arising in connection with the presentation. The information presented or contained in this presentation speaks as of the date of this presentation and is subject to change without notice.

Certain statements in this presentation, and other statements that the Company may make, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), Section 21E of the Securities Exchange Act of 1934, as amended., or the Private Securities Litigation Reform Act of 1995. These statements reflect the Company's intent, beliefs or current expectations about the future. These statements can be recognized by the use of words such as "expects," "plans," "will," "estimates," "projects," "intends," "anticipates," "believes," "confident" or words of similar meaning. These forward-looking statements are not guarantees of future performance and are based on a number of assumptions about the Company's operations and other factors, many of which are beyond the Company's control, and accordingly, actual results may differ materially from these forward-looking statements. The Company or any of its affiliates, advisers or representatives has no obligation and does not undertake to revise forward-looking statements to reflect future events or circumstances.

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No securities of the Company may be sold in the United States without registration with the United States Securities and Exchange Commission (the "SEC") or an exemption from such registration pursuant to the Securities Act and the rules and regulations thereunder. No part of this presentation shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. Specifically, these materials do not constitute a "prospectus" within the meaning of the Securities Act. This presentation does not contain all relevant information relating to the Company or its securities, particularly with respect to the risks and special considerations involved with an investment in the securities of the Company and is qualified in its entirety by reference to those risks more fully discussed in the section titled "Risk Factors" in the Company's most recent annual report on Form 20F, as well as discussions of potential risks, uncertainties, and other important factors in the Company's subsequent filings with the SEC.

2

Gracell At A Glance

We are a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies to address major industry challenges and fulfill unmet medical needs in the treatment of cancer. We aim to disrupt conventional approaches to CAR-T cell therapies with our proprietary technology platforms-FasTCAR and TruUCAR.

Key Financial Highlights

Cash & short term investments	$331 M (as of 3/31/21)
ADS Outstanding	~69.0 M (as of 3/31/21)
Net proceeds from IPO	$220 M

Key Company Highlights

Nasdaq	GRCL
History	Founded In 2017
Headquarter	China
Operations	China and US

3

Investment Highlights

Two proprietary technology platforms representing game changing advances in the CAR-T industry

➢ FasTCAR: Next-day manufacturing for autologous CAR-T cell therapy

• TruUCAR: Novel CAR designs enabling "off-the-shelf",stand-alone allogeneic therapy

Rich pipeline of first-in-class autologous and allogeneic cell therapy candidates with highly competitive data in several indications

Highly experienced management team with expertise in discovering and developing CAR-T therapies

Strong financial position to support R&D and corporate strategies

4

Gracell's Leadership

William Cao, PhD, BM

Founder, Chairman & CEO

• 30+ years of biotech and R&D experience
• Co-founderand former CEO of Cellular Biomedicine Group (formerly Nasdaq:CBMG)
• Former senior scientific management positions at Chiron (Novartis and Bayer) and Affymetrix (ThermoFisher)
• 80+ issued patents & applications for advanced cell therapies

Martina Sersch, MD, PhD

Chief Medical Officer

• MD with 25+ years of experience in academia and industry including international experience
• Extensive Cell and Gene therapy experience
• Multiple successful global filings / approvals in hematological and solid malignancies
• Former CMO of a cell and gene therapy company (Nasdaq: MBIO)
• Former Executive Director, Early and Late- stage Hematology Global Development Lead at Amgen
• Former senior management in Clinical Development and Medical Affairs at Genentech/Roche and Pfizer

Kevin Xie, PhD, MBA

Chief Financial Officer

• 20+ years of healthcare industry and investment experience
• Former President of Fosun Healthcare Holdings and Chief Representative of Fosun New York
• Former Healthcare Sector Head at Scopia Capital
• Former Managing Director at Great Point Partners
• BoD of ViewRay (Nasdaq: VRAY) & Alpha Healthcare Acquisition Corp (Nasdaq: AHAC)

Jenny Ni, MD, PhD

Chief Technology Officer

• 25+ years of experience in gene & cell therapy, vaccine and contract manufacturing service at international pharmaceutical and biotech companies
• Successfully led CMC development of five IND filings / approvals for hematological and solid malignancies
• Former Head of Process Development at both Pfizer and Allogene Therapeutics
• Former senior Tech-Operations position at VIRxSYS Inc., bringing the first ever lentiviral vector modified autologous T cell product into clinical stage

5